☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Transthyretin Amyloid Cardiomyopathy
Pfizer's Vyndaqel (tafamidis- 61mg) Receives EC's Approval as the First Therapy to Treat Transthyretin Amyloid Cardiomyopathy in t...
February 18, 2020
Pfizer's Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) Receive FDA's Approval for Transthyretin Amyloid Cardiomyopathy
May 6, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.